Azenta, Inc.

Valuation Analysis

About the Company

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing,

Azenta, Inc. Stock at a Glance

Azenta, Inc. (AZTA) is currently trading at $22.59 with a market capitalization of $1B. The 52-week range spans from $15.93 to $41.73; the current price is 45.9% below the yearly high. Year-over-year revenue growth stands at +1.0%.

💰 Dividend

Azenta, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

5 analysts rate Azenta, Inc. (AZTA) on consensus: Buy. The average price target is $26.20, implying +15.98% from the current price. Analyst price targets range from $20.00 to $33.00.

Azenta, Inc.: The Investment Case in Detail

Azenta, Inc. (AZTA) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 15.98% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue growth has slowed to just 1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 20.04% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.53, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (20.04%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Azenta, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.